Company Description
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test.
In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders.
The company also provides cancer screening and diagnostic test products. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915.
Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
| Country | United States |
| Founded | 1888 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 115,000 |
| CEO | Robert Ford |
Contact Details
Address: 100 Abbott Park Road, Lake County Abbott Park, Illinois 60064-6400 United States | |
| Phone | 224 667 6100 |
| Website | abbott.com |
Stock Details
| Ticker Symbol | ABT |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000001800 |
| CUSIP Number | 002824100 |
| ISIN Number | US0028241000 |
| Employer ID | 36-0698440 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert B. Ford | Chairman, President and Chief Executive Officer |
| Philip P. Boudreau | Chief Financial Officer and Executive Vice President of Finance |
| Daniel Gesua Sive Salvadori | Executive Vice President and Group President of Established Pharmaceuticals and Nutritional Products |
| Christopher J. Scoggins | Executive Vice President of Diabetes Care |
| Lisa D. Earnhardt | Executive Vice President and Group President of Medical Devices |
| Sabina Ewing | Senior Vice President of Business and Technology Services and Chief Information Officer |
| Michael Comilla | Vice President of Investor Relations. |
| Erica L. Battaglia | Vice President and Chief Ethics and Compliance Officer |
| Elizabeth Cushman | Executive Vice President, General Counsel and Secretary |
| Melissa Brotz | Senior Vice President of Global Marketing and External Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 23, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 23, 2026 | 8-K | Current Report |
| Mar 13, 2026 | ARS | Filing |
| Mar 13, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 13, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 9, 2026 | 8-K | Current Report |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |